Skip to content
Back to Investors
SCVC

SCVC

Venture Capital

SCVC is a venture capital firm that invests in early-stage deep tech spinouts.

Portfolio

6

companies

Investment by month

By category

  • AI/ML£25.5M
  • Uncategorised£5.3M
  • HealthTech£4.7M
  • IndustrialTech£4.6M
  • Semiconductor£4.0M
  • Other£1.5M

By location

  • London£25.5M
  • Sheffield£5.3M
  • Scotland£4.7M
  • Birmingham£4.6M
  • Bristol£4.0M
  • Other£1.5M

Portfolio companies

D

Delta.g

Delta.g develops field-tested quantum sensors that deliver real-time spatial intelligence.

HB

Houdini Bio

Houdini Bio develops software that redesigns therapeutic DNA so the body does not attack it.

N

Nebu-Flow

Nebu-Flow develops advanced nebuliser technology for pharmaceutical delivery.

P

Pixel-Flo

Pixel-Flo develops continuous-flow mass transfer technology for microLED screen manufacturing.

PB

Portal Biotech

Portal Biotech delivers single-molecule protein sequencing technology to transform proteomics and drug discovery.

Zero Point Motion

Zero Point Motion

Zero Point Motion develops ultra-sensitive motion sensors for GPS-denied environments.


Team

JW

John Williams

general partner


Recent investments

Seed
£5.3M

The University of Sheffield spinout raised the capital from an international syndicate led by Northern Gritstone to scale its continuous-flow assembly process.

"This investment allows us to expand our team and demonstrate our unique technology on a commercial coating system, enabling partnership and evaluation by display manufacturing partners. We are proud to have a fantastic international consortium of complementary investors led by Northern Gritstone supporting our international ambitions to enable huge new market opportunities for microLED"
— Rick Smith, CEO and co-founder
Pre-Seed
£1.5M

SCVC led the pre-seed round with backing from Deep Science Ventures and Cambridge Enterprise VC to help the startup expand its team and partnerships.

"Cellular machinery still rejects these therapies, limiting long-term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design,"
— Jonathan Cohen-Gold, Chief Executive
Seed
£4.6M

Serendipity Capital led the round with participation from NSSIF and SCVC.

"We’re thrilled by the strong investor support at this early stage. This raise is more than capital; it’s a vote of confidence in our mission to make quantum sensing operational. We’re building the tools to see what others can’t, in places that matter most, from hidden sinkholes to critical infrastructure. With this funding, we’re accelerating our roadmap to deliver smaller and more nimble field-ready systems."
— Tony Lowe, CEO
Series A
£25.5M

The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.

"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."
— Andy Heron, Co-founder and CEO